Publications

1.  Contemporary treatment principles for early rheumatoid arthritis: a consensus statement. P Kiely, A  Brown, C Edwards, D O’Reilly, A Östör, M Quinn, A Taggart, P Taylor, R Wakefield, and P Conaghan Rheumatology, July 2009; 48: 765 – 772.

2. Tolerability of methotrexate and leflunomide combination therapy for inflammatory arthritis in routine clinical practice: results of a four-centre study. A Kaul, D O’Reilly, R Slack, D.Collins, J Walmsley, O Duke and P Kiely Rheumatology, September 2008; 47: 1430 – 1431.

3. Imatinib Treatment of Seropositive Arthritis in a Young Woman with Chronic Myeloid Leukemia. P Ames, W Aye, C Beatty, and D O’Reilly J Rheumatol August 2008 35(8):1682.

4. Quantification of cold challenge responses in primary Raynaud’s phenomenon and systemic sclerosis associated Raynaud’s phenomenon. D O’Reilly, L Lyon, K el Hadidi and MIV Jayson. Ref: Annals Rheumatic Diseases 1992; 51: page nos. 1193 to 1196.

5. Sustained-Release Transdermal Glyceryl Trinitrate patches as a treatment for primary and secondary Raynaud’s Phenomenon. L.S. Teh, J. Manning, T. Moore, M.P. Tully, D O’Reilly, M.I.V. Jason. British Journal of Rheumatology 1995;34: 636 – 641.

6. Carcinoma of the colon presenting with dyspepsia. D O’Reilly, RG Long. Postgraduate Medical Journal 1987; 63: 215-216.

Presentations

1. E57. Use of Subcutaneous Methotrexate in Inflammatory Arthritis in East of England: A Survey Looking at Attitudes Practices and Barriers. R Yakoob, E Ntatsaki, D O’Reilly, M Tripathi, P Sharma, S Dahiy. Rheumatology (2016) 55 (suppl_1): i186

2. E51. Methotrexate in Inflammatory Polyarthritis: Dose, Route of Administration and Persistence over Five Years. R O’Reilly, R Slack, S Bhagat, V Rajagopal, D O’Reilly. Rheumatology (Oxford) (2015) 54 (suppl_1): i191.

3. E49. How to Deliver Good Outcomes in Rheumatoid Arthritis and Maximize Capacity with a Multidisciplinary Approach. R O’Reilly, R Slack, S Bhagat, V Rajagopal, D O’Reilly. Rheumatology (Oxford) (2015) 54 (suppl_1): i191.

4. The Impact of Treat to Target on 1-Year Real-World Outcomes in Patients with Rheumatoid Arthritis. A Tan, M Buch, D O’Reilly, T Sheeran, S Keidel, S Chitale, P Emery. Rheumatology (Oxford) (2016) 55 (suppl_1): i96-i96.

5. Predictors of Outcome at 1-Year in Patients with Rheumatoid Arthritis: Results from the UK Treat-to-Target Audit. A Tan, M Buch, D O’Reilly, T Sheeran, S Keidel, S Chitale, P Emery. Rheumatology (Oxford) (2016) 55 (suppl_1): i96-i96.

6. Compliance with Treat to Target Recommendations & Its Impact on Control of Rheumatoid Arthritis – Interim Results of A UK Multicentre Audit. M. Buch, D. O’Reilly, T. Sheeran, S. Keidel, P. Emery, on behalf of T2T Initiative Group Ann Rheum Dis 2014;73:Suppl 2 390 doi:10.1136/annrheumdis-2014-eular.3126

7. Would prior testing of Anti-Cyclic Citrullinated Antibodies (anti CCP) Help with Decision Making at the First Visit to an Early Arthritis Clinic?J Thomas, R Slack, T Catchpole, P Johansen, D O’Reilly. Presentation Number: 1825 American College of Rheumatologists Conference 2007.

8. Improved outcome from Chronic Obstructive Pulmonary Disease (COPD) exacerbations in a DGH following introduction of an Oxygen prescription and guidance form. DG Kiely, L Pierce, D O’Reilly and CM Laroche. Presented to the British Thoracic Society November 1998.Thorax 1998;53 (Suppl 4).

9. Collagen autoantibodies in juvenile onset arthritis. D O’Reilly, PJL Holt, I Collins, JH Keen and K Morgan. Presented to the British Society for Rheumatology July 1992.

10. Interactions between phenytoin and antituberculous drugs. D O’Reilly, GS Basran, B Hourihan and JT Macfarlane. Thorax 1987; 42: 736 (abst). Presented to the British Thoracic Society, July 1987.

11. Use of endoscopic biopsy to diagnose disaccharidase deficiency. J Smith, J Emoah, D O’Reilly, JF Mayberry and RG Long. Gut 1987; 28: A1398 (abst). Presented to the British Society of Gastroenterology, Sept 1987.

12. Use of pneumococcal antigen detection and C-reactive protein estimation in the diagnosis of acute chest infection. D O’Reilly and RG Finch. Presented to the Clinical Infection Society, June 1986.